| Literature DB >> 33069788 |
Shujuan Chen1, Lin Dong2, Hongfeng Quan3, Xirong Zhou4, Jiahua Ma5, Wenxin Xia6, Hao Zhou7, Xueyan Fu8.
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE: Tussilago farfara L. (commonly called coltsfoot), known as a vital folk medicine, have long been used to treat various respiratory disorders and consumed as a vegetable in many parts of the world since ancient times. AIM OF THE REVIEW: This review aims to provide a critical evaluation of the current knowledge on the ethnobotanical value, phytochemistry, pharmacology, toxicity and quality control of coltsfoot, thus provide a basis for further investigations.Entities:
Keywords: Ethnopharmacology; Pharmacology; Phytochemistry; Quality control; Toxicity; Tussilago farfara L.
Mesh:
Substances:
Year: 2020 PMID: 33069788 PMCID: PMC7561605 DOI: 10.1016/j.jep.2020.113478
Source DB: PubMed Journal: J Ethnopharmacol ISSN: 0378-8741 Impact factor: 4.360
Fig. 1Images of Tussilago farfara L. (coltsfoot) (a) whole-plant of coltsfoot picture adapted from (Tobyn et al., 2011); (b) leaves of coltsfoot; (c) flowers of coltsfoot.
Fig. 2Distribution map of coltsfoot Native Introduction reproduced from (http://plantsoftheworldonline.org/taxon/urn:lsid:ipni.org:names:30006161-2).
Traditional and clinical applications of Tussilago farfara L. (coltsfoot).
| Herbal formulations | Ingredients | Country/Region | Traditional uses/modern used | Preparation and administration | References |
|---|---|---|---|---|---|
| The lung cleansing and detoxifying decoction (LCDD) | China | Widely used in treating COVID-19 Patients | Decoction | ||
| Skin pigmentum | Farfarae folium | Spain | Bacterial skin disease (Anthrax, Boils) | Apply leaves on the skin | |
| Hormone Rejuvenator | Europe | Nd | Capsule | ||
| Bronchostad® | Made from coltsfoot leaves | Europe | which can also be used to prepare liquid and solid extracts | Instant tea | |
| Recipe | Coltsfoot | Europe | To heal ‘buchas’, cough, shortness of breath, asthma | Decoction | |
| Tobacco | Coltsfoot | Europe | Relives asthma and old bronchitis, catarrh and other lung troubles | Tobacco | |
| Kuan Donghua Tang | China | For erupting cough | Decoction | ||
| Kuan Hua Tang | China | Treatment of lung carbuncle and chest full of cold, pulse count, dry throat, great thirst, turbid saliva, stinky pus like japonica rice gruel | Decoction | ||
| Ding Chuan Tang | China | Treating for bronchial asthma, asthma bronchitis etc. | Decoction | ||
| Kuan Dong Jian | China | Treatment of cough with cold | Decoction | ||
| Zi Wan San | China | Cure a persistent cough | pulvis | ||
| Jiu Xian San | China | Chronic Cough of Qi and blood deficiency | pulvis | ||
| Bai Hua Gao | China | Treat asthma, cough and sputum with blood | Pill | ||
| External preparation | The flower buds of coltsfoot | China | Treatment of hemorrhoid and fistula | The flower buds of coltsfoot into fine powde and then rapply with Water | |
| Alcohol extract | The flower buds of coltsfoot | China | Treat asthma | Oral 5 ml (equivalent to 6 g of crude drug, 3 times a day, observation for 1 week | |
| Compound coltsfoot injection | China | Treatment of chronic bronchitis and anti-hypertensive effect | Each intramuscular injection of 2 ml, continuous medication for 10 days | ||
| External preparation | The flower buds of coltsfoot | China | Treatment of chronic osteomyelitis | Make a paste, apply it to a disinfecting cloth, wash the patients with sinus tract with light saline, according to the size of the injured surface |
Notes.
“Qi”: In ancient China, it is believed that Qi constitutes one of the basic substances of the body and maintain human life activities. People in China deemed that everything in the universe resulted from the movement and changed of Qi.
“Cold”: pain that is worse for cold and improved by warmth.
Nd: no date.
Some Tussilago farfara L. (coltsfoot) related patents.
| Food products | Title of the patent | Information about the patent | Patent numbers and date approved | Country |
|---|---|---|---|---|
| Medicament | Composition, comprising tussilagone compound isolated from | The invention relates to the preparation of tussilagone from | KR20180056599 2018-05-17 | Korea |
| Medicament | The pharmaceutical Composition for prevention or treatment of cancer comprising an extract of | The invention relates to a new TRAIL sensitizer of | KR20130065367 2013-06-07 | Korea |
| Medicament | Use of extract from leaves of | The use of the extract from the leaves of | UAU201312799U 2013-11-04 | USA |
| Medicament | Composition and health function food for treating brain cancer comprising | The invention relates to a novel use of | KR20110012204 2011-02-11 | Korea |
| Medicament | Analgesic and anti-inflammatory herbal remedy, useful e.g. for external application to treat injuries and strains, comprising mixture of extracts of alder tree cones and coltsfoot leaves | A new natural herbal remedy (I), with analgesic and anti-inflammatory activity, comprises a mixture of: (a) an extract of alder tree cones and (b) an extract of coltsfoot leaves | DE20011028027 2001-06-08 | Germany |
| Medicament | Coltsfoot flower effective part with anti-influenza effect and preparation method and application | Dried coltsfoot flowers serve as raw materials, which n-butyl alcohol extract is simple in process and low in cost, and can be used for preparing drugs for preventing and treating H1N1 influenza | CN201810585765 2018-06-08 | China |
| Decoction | Traditional Chinese Medicines decoction of common coltsfoot flower for treating asthma and preparation method thereof | Comprising raw materials in parts by weight: coltsfoot flower, and radix | CN201210197598 2012-06-14 | China |
| Food therapy soup | Manufacturing method for food therapy soup of common coltsfoot flowers and lily bulbs used for cough due to dryness | An herbal nutraceutical formulation for relieving a cough, and has a certain effect on the cough due to dryness. comprising: 20 dates of red dates, 15 g of common coltsfoot flowers, 50 g of lily bulbs and a proper amount of rock sugar | CN201710372730 2017-05-24 | China |
| Herb jelly | Herb jelly, useful as parfait and food supplement, comprises mullein blossoms, stinging nettle leaves, rosemary leaves, coltsfoot, thyme, Veronica leaves, ground-ivy, sage leaves, brewing water and gelling sugar | Herb jelly comprises: mullein blossoms (3 parts), stinging nettle leaves (1 part), rosemary leaves (1 part), coltsfoot (2 parts), thyme (1 part), Veronica leaves (1 part), ground-ivy (1 part), sage leaves (2 parts), brewing water (42 Parts for processing 29 parts of brew), gelling sugar 1:1 (50 Parts), Activity: virucide | DE20072006932U 2007-05-14 | Germany |
| Flower tea | Preparing method of coltsfoot flower tea | Obtained wall-broken flower powder by a grinding method and mixed tea flowers, coltsfoot flowers, corn flowers and longan, which is nutritious, tasty and fragrant and enables the human body to absorb nutrition of the tea fully | CN20161083529 2016-02-12 | China |
| Flower powder tea | Preparation method of tea containing coltsfoot flower powder | The invention discloses a preparation method of tea containing coltsfoot flower powder, which method not only preserve the tea aroma, but also play its pharmaceutical values of moistening lungs to lower the internal heat, reducing the phlegm and stopping cough of the coltsfoot flower | CN201410562552 2014-10-19 | China |
| Beverage | Common coltsfoot flower health-care beverage | The product containing raw materials in parts by weight, coltsfoot flowers (4–5), mint (4–5), | CN201510658241 2015-10-14 | China |
| Wine | Traditional Chinese medicines wine containing lily and common coltsfoot flower | With raw materials in parts by weight: lily (240), coltsfoot flowers (240), | CN201510644140 2015-09-23 | China |
| Wine | Coltsfoot flower health care wine for treatment of asthma | Taking parts of coltsfoot flower (25), ephedra rachis (15), cortex mori radices (13), Chinese angelica (16), perilla seed (14) and | CN201210380110 2012-10-10 | China |
| Paste | Alcoholic extract pastes of common coltsfoot flower and preparation method and application thereof | After carrying out coarse grinding on common coltsfoot flower, extracting by ethanol, filtering, distilling and concentrating to prepare the alcoholic extract paste product, which can take effects of moistening lung, reducing phlegm, relieving a cough and relieving asthma in the smoking process of a patient | CN20121038413 2012-02-17 | China |
| A cosmetic composition or a food and drink | Phototoxicity inhibitor comprising extract from | A new and safe specific ingredient as a phototoxicity inhibitor. comprising: ≥0.07% chlorogenic acid content and ≥0.01% caffeic acid content | JP20010059727 | Japan |
Phytochemical Constituents of coltsfoot.
| No. | Chemical constituents | Reference |
|---|---|---|
| Tussilagonone | ||
| 7β-(4-methylse-necioyloxy)-oplopa-3(14)E,8(10)-dien-2-one | ||
| 7β-senecioyloxyoplopa-3(14)Z,8(10)-dien-2-one | ||
| 7β-angeloyloxyoplopa-3(14)Z,8(10)- dien-2-one | ||
| 7β-[3-ethyl-cis-crotonoyloxy]-lα-[2-methylbutyryloxy]-3,14-dehydro-Z-notonipetranone | ||
| 7β-[3-ethyl-cis-crotonoyloxy]-lα-[2-methylbutyryloxy]-3,14-dehydro-E-notonipetranone | ||
| 1α-angeloyloxy-7β-(4-methylsenecioyloxy)-oplopa-3(14)Z, 8(10)-dien-2-one | ||
| 1α,7β-di(4-methyl-senecioyloxy)-oplopa-3(14)Z,8(10)-dien-2-one | ||
| 1α-hydroxy-7β-(4-methylsenecioyloxy)-oplopa-3(14)Z,8(10)-dien-2-one | ||
| Farfarone D | ||
| 7β-[3-ethyl-cis-crotonoyloxy]-lα-[3-methylvaleric]-3,14-dehydro-Z-notonipetranone | ||
| 14-acetoxy-7β-(3′-ethylcis-crotonoyloxy)-lα-(3′-methylvaleric)-notonipetranone | ||
| Tussilagone (TSL) | ||
| 14(R)-hydroxy-7β-(4-methyl-senecioyloxy)-oplop-8(10)-en-2-one | ||
| 14-acetoxy-7β-senecioyloxy-notonipetranone | ||
| 14-acetoxy-7β-angeloyloxy-notonipetranone | ||
| 14-acetoxy-7β-(3′-ethylcis-crotonoyloxy)-lα-(2′-methylbutyryloxy)-notonipetranone | ||
| 14(R)-hydroxy-7β-isovaleroyloxyoplop-8(10)-en-2-one | ||
| 14(R)-acetoxy-7β-isovaleroyloxyoplop-8(10)-en-2-one | ||
| Tussfarfarin B | ||
| 7β-angeloyloxy-14-hydroxy-notonipetranone | ||
| 7β-(3-ethyl-cis-crotonoyloxy)-14-hydroxy-1α-(2-methylbutyryloxy)-notonipetranone | ||
| 7β-(3-ethylcis-crotonoyloxy)-14-hydroxy-notonipetranone | ||
| 14-acetoxy-7β-(3-ethyl-cis-crotonoyloxy)-notonipetranone | ||
| Tussilagofarin | ||
| Neotussilaoglactonel | (W. | |
| β-oploplenone | ||
| Tussilaoglactonel | ||
| 1β,8-bisangeloyloxy-3α,4α-epoxybisabola-7(14),10-dien-2-one | ||
| 1β-(3-ethyl-ciscrotonoyloxy)-8-angeloyloxy-3α,4α-epoxybisabola-7(14),10-dien-2-one | ||
| 1α-(3-ethyl-cis-crotonoyloxy)-8-angeloyloxy-3β,4β-epoxy-bisabola-7(14),10-diene | ||
| 1α,8-bisangeloyloxy-3β, 4β-epoxy-bisabola-7(14),10-diene | ||
| 8-angeloylxy-3,4-epoxy-bisabola7(14),10-dien-2-one | ||
| (1R,3R,4R,5S,6S)-1-acetoxy-8-angeloyloxy-3,4-epoxy-5-hydroxybisabola-7(14),10-dien-2-one | ||
| (1R,3R,4R,5S,6S)-1,5-diacetoxy-8-angeloyloxy-3,4-epoxybisabola-7(14),10-dien-2-one | ||
| (3R,4R,6S)-3,4-epoxybisabola-7(14),10-dien-2-one | ||
| 1α,5α-Bisacetoxy-8-angeloyloxy-3β,4β-epoxy-bisabola-7(14),10-dien-2-one | ||
| Tussfararin A | ||
| Tussfararin B | ||
| Tussfararin C | ||
| Altaicalarin C | ||
| Farfarone B | ||
| Farfarone A | ||
| Tussfararin D | ||
| Tussfararin E | ||
| Tussfararin F | ||
| (4R,6E)-2-acetoxy-8-angeloyloxy-4-hydroxybisabola-2,6,10-trien-1-one | ||
| (−)-cryptomerion | ||
| (9S)-altaicalarin B | ||
| (−)-spathuleno | ||
| Ligucyperonol | ( | |
| Tussfarfarin A | ||
| Arnidiol | ||
| Faradiol | ||
| Bauerenol | ||
| Isobauerenol | ||
| Bauer-7-ene-3β,16α- diol | ||
| Apigenin | ||
| Luteolin | ||
| Quercetin | ||
| Quercetin 3-O-β-L-arabinopyranoside | ||
| Quercetin 3-O-β-D-glucopyranoside | ||
| Hyperoside | ||
| Rutin | ||
| Kaempferol | ||
| Kaempferol-3- | ||
| Kaempferol-3- | ||
| Kaempferol-3- | ||
| Kaempferol-3- | ||
| Kaempferol-3-O-rutinoside | ||
| Benzoic acid | ||
| Syringic acid | ||
| Gallic acid | ||
| 4-hydroxyacetophenone | ||
| 4-hydroxybenzoic acid | ||
| Trans-cinnamic acid | ||
| Ferulic acid | ||
| Isoferulic acid | ||
| P-coumaric acid | ||
| Sinapic acid | ||
| Caffeic acid | ||
| Chlorogenic acid | ||
| Cryptochlorogenic acid | ||
| Neochlorogenic acid | ||
| Methyl 3-O-caffeoyl quinate | (Liu, Y.F. et al., 2007) | |
| Methyl 4-O-caffeoyl quinate | (Liu, Y.F. et al., 2007) | |
| 3,4-di- | ||
| Methyl 3,4-di- | ||
| 3,5-di- | ||
| Methyl 3,5-di- | ||
| 4,5-di- | ||
| Methyl 4,5-di- | ||
| 4,5-di-O-caffeoylquinic acid butyl ester | ||
| Rosmarinic acid | ||
| 6-methoxy-2,2-dimethylchroman-4-ol | ||
| 6-methoxy-2,2-dimethylchroman-4-ol | ||
| 6-acetyl-2,2-dimethylchroman-4-one | ||
| 6-acetyl-2,2-dimethylchroman-4-one | ||
| 2,2-dimethyl-6-(1-hydroxyethyl) | ||
| 2,2-dimethyl-6-(1-hydroxyethyl) | ||
| 6-(1-methoxyethyl) | ||
| 6-(1-methoxyethyl) | ||
| 6-(1-methoxyethyl) | ||
| 6-(1-methoxyethyl) | ||
| 6-(1- ethoxyl) | ||
| 6-(1- ethoxyl) | ||
| 6-(1- ethoxyl) | ||
| 6-(1- ethoxyl) | ||
| 6-acetyl-7-hydroxy-2,3-dimethylchromone | ||
| 6-carboxyl-7-hydroxy-2,3-dimethylchromone | ||
| 6-(1-Ethoxyethyl)-2,2- dimethylchroman-4-ol | ||
| 6-hydroxy-2,2-dimethylchroman-4-one | ||
| 1-(4-hydroxy-2,2-dimethyl-chroman-6-yl)-ethanone | ||
| 2,2-dimethyl-6-(1-hydroxyethyl)- chroman-4-one | ||
| 6-(1-hydroxyethyl)-2,2-dimethylchroman-4-ol | ||
| 6-acetyl-2,2-dimethylchroman-4-one | ||
| 1-[(4S)-3,4-dihydro-4-hydroxy-2,2-dimethyl-2H-1-benzopyran-6-yl]-ethanone | ||
| Tussilagofarol | ||
| 2-{[(2S)-2-Hydroxypropanoyl]amino}benzamide | ||
| Tussilagine | ||
| Tussilaginine | ||
| Isotussilagine | ||
| Neo-tussilagine | ||
| Neo-isotussilagine | ||
| Senkirkine | ||
| Senecionine | ||
| Integerrimine | ||
| Seneciphylline | ||
| Senecivernine | ||
| 2-pyrrolidineactic acid | ||
| Tussilaginic acid | ||
| Isotussilaginic acid | ||
| Adenine | ||
| Adenosine | ||
| 3β-hydroxy-7α-ethoxy-24β-ethylcholest-5-ene 4 | ||
| 2-formyl-5-hydroxymethyl-furan | ||
| Sessiline | ||
| Hex-3-en-1-ol 1-O-β-D-glucopyranoside | ||
| Benzyl-β-D-glucopyranoside | ||
| Glaberide I | ||
| Syringaresinol | ||
| β-sitosterol | ||
| Sitosterone | ||
| 5-ethoxymethyl-1H-pyrrole-2-carbaldehyde | ||
| Ixocarpalactone B | ||
| 7β-hydroxysitosterol | ||
| 7α-hydroxysitosterol | ||
| Daucosterol | ||
| Stigmasterol | ||
| Phthalic acid | ||
| Moluccanic acid methyl ester | ||
| Bis (2-ethylhexyl) phthalate | ||
| Dibutylphthalate | ||
| Loliolide | ||
Fig. 3The sesquiterpenoids compounds isolated from coltsfoot.
Fig. 4The triterpenoid isolated from coltsfoot.
Fig. 5The flavonoids and flavonoid glycosides isolated from coltsfoot.
Fig. 6The phenolic compounds isolated from coltsfoot.
Fig. 7The chromones and its derivatives isolated from coltsfoot.
Fig. 8The alkaloids isolated from coltsfoot.
Fig. 9The other phytochemical compounds isolated from coltsfoot.
Example of Anti-inflammatory activity potential of coltsfoot.
| Assay | Solvent/components | Model, method | Concentration/Dosage | Positive control | Findings | Reference |
|---|---|---|---|---|---|---|
| Anti-inflammatory | TGN (1) | IMQ-induced psoriatic skin lesions in HaCaT keratinocytes ( | TGN (1 or 5 nmol/100 μl) | CAL SFN and tBHQ | ↓ NF-κB and STAT3 and psoriasis-associated markers via Nrf2 activation | (Lee, J. et al., 2019) |
| Anti-inflammatory | TGN (1) | LPS-stimulated RAW 264.7 cells 12-O-tetradecanoylphorbol-13-acetate-induced skin inflammation in mice ( | TGN (2.5,5 and 10 μM) LPS (1 μg ml−1) | Dexamethasone (5 μM in 0.2 mL DMSO/acetone) | TGN (2.5 and 5 μM) reduced iNOS and COX-2 expression and ↑ Nrf2/HO-1 and ↓ NF-κB signaling pathway, similar to dexamethasone (5 μM) | |
| Anti-inflammatory | L-652,469( | Carrageenan-induced rat hindpaw edema, | 15–50 mg kg−1 p.o. 50,100 mg p.o. | Nitrendipine | ↓the PAF-induced rat foot edema and the first phase of carrageenan-induced rat hindpaw edema. | |
| Anti-inflammatory | TSL ( | DSS-induced acute colitis mice ( | TSL (0.5 or 2.5 mg kg−1) | without DSS | Attenuated weight loss, colon shortening and severe clinical signs ↓ the activation of NF-κB and inducing Nrf2 pathways | |
| Anti-inflammatory | TSL ( | LPS-stimulated RAW 264.7 cells CLP-Induced Septic Mice ( | TSL (10,20,30 μM) TSL (1,10 mg kg−1) | No treatment | ↓ expression of COX-2 and TNF-α in PAM and serum level of NO, PGE2, TNF-α and HMGB1↓ MAP Kinases and NF-κB | |
| Anti-inflammatory | TSL ( | The induction of HO-1 in murine macrophages ( | TSL (0–30 μM) LPS (1 μg ml−1 | α-tubulin | TSL-induced HO-1 protein expression in a dose- and time-dependent manner without the induction of HO-1 mRNA expression | |
| Anti-inflammatory | TSL ( | LPS-activated BV-2 cells ( | TSL (5,10 μg ml−1) TSL (2–30 μM) | LPS-media | Dose-dependent ↓ NO and PGE2 production with IC50 values of 8.67 μM, 14.1 μM, respectively, for neuro-inflammatory diseases | |
| Anti-inflammatory | 70% ethanol buds) | Brain ischemia was induced in Sprague-Dawley rats ( | TF (300 mg kg−1 P.O.) | MK-801(i.p) 1 mg kg−1 | ↓ the neuronal death and the microglia/astrocytes activation in ischemic brains, also ↓ cytokines |
Notes.
↑: activated, ↓: inhibition, TF, Tussilago farfara L.; HO-1, Heme oxygenase-1; dextran sulfate sodium; SFN, Sulforaphane; tBHQ, tert-butylhydroquinone; CAL, Calcipotriol hydrogen peroxide; TPA:12-O-tetradecanoylphorbol-13-acetate; IMQ, imiquimod; NF-κ B: nuclear factor-kappa B; Nrf2: nuclear factor (erythroid-derived 2)-like 2; NO: nitric oxide.
Example of anticancer (anti-proliferation) potential of coltsfoot.
| assay | Solvent/components | Model/method | Concentration/Dosage | Positive control | Findings | Reference | |
| Anti-cancer | Sesquiterpenoids (flower bud) | Three cancer cell lines (AGS, HT-29 and PANC-1) | (50.0,25.0, 12.5,6.25, 3.12 μM) Au or Ag | N/d | The IC50 values of PANC-1 cells were the lowest: 166.1 μM Ag for TF-AgNPs and 71.2 μM Au for TF-AuNPs | ||
| Anti-cancer | MeOH fraction (leaves, rachis) | Co-treatment of Huh7 cells with TF and TRAIL induced apoptosis ( | TF (200 μg ml−1) and TRAIL (100 ng ml−1) | DMSO 0.1% (v/v). | ↓ inhibition of the MKK7-TIPRL interaction and ↑ in MKK7/JNK phosphorylation | ||
| Anti-cancer | 55% acetonitril ECN ( | TNBC MDA-MB-231 Cells ( | ECN (0–15 μ M) | Staurosporine (IC50 = 0.3 μM) | ↓ the JAK–STAT3 signaling pathway and the expression of STAT3 target genes inducing apoptosis of TNBC MDA-MB-231 cells (IC50 = 3.27 μg ml−1) | ||
| Anti-proliferation | TSL ( | SW480 and HCT116 colon cancer cell lines ( | TSL (2,10, and 30 μM) | DMSO | ↓ the β-catenin activity and ↓the expression of target genes of the Wnt/β-catenin signaling pathway dose dependently | ||
| anti-angiogenesis | TSL ( | HUVEC ( | TSL (3, 10, and 30 μM), TSL (1 and 10 mg kg−1) | Cabozanitib (XL184) (5 μM) (30 mg kg−1) | Anti-proliferation via ↓ VEGFR2 signaling pathway and 30 μM (TSL) more effect than cabozanitib (5 μM) | ||
| Anti-cancer | Polysaccharides (TFPB1) | A549 human non-small lung cancer cell line ( | TFPB1 (0–1000 μg ml−1) | N/d | In a dose-dependent manner anti-proliferative and anti-apoptotic effect via modulated by the downregulation of PI3K/Akt pathway | ||
Notes.
↑Activated, ↓Inhibition, N/d, no date; TF, Tussilago farfara L.; AgNPs, silver nanoparticles; AuNPs, gold nanoparticles; HUVEC, tube formation of primary human umbilical vascular endothelial cell; VEGF, vascular endothelial growth factor; AGS, human gastric adenocarcinoma cell; HT-29, human colorectal adenocarcinoma cell; PANC-1, human pancreas ductal adenocarcinoma cell; TNBCs, Triple-negative breast cancers; MDA-MB-231, Human Breast Cancer Cells; MKK7, mitogen protein kinase kinase 7; JNK, c-Jun N-terminal kinase; TIPRL, TOR signaling pathway regulator-like protein; STAT3, Signal transducer and activator of transcription 3; JAK, Janus kinase.
Examples of antimicrobial screening conducted on different Parts of Tussilago farfara L. (coltsfoot).
| Assay | Plant part | Solvent/extracts | Test method and organisms/virus | Findings | Reference |
|---|---|---|---|---|---|
| Antibacterial | Flower bud | n-hexane-acetonitrile-water | Better activity | ||
| Antibacterial | Flowers | Essential oil, dodecanoic acid | Essential oil antibacterial activity against | ||
| Antibacterial | Leaf | EtOAc, MeOH, Water | Inhibitory effect the MIC and the MBC ranged from 0.06 mg ml−1 to 0.40 mg ml−1, 0.124 mg ml−1 to 0.45 mg ml−1 respectively | ||
| Antibacterial | Flowers and rachis | MeOH | Antimicrobial antibacterial activity with MIC50 = 48.01–64 μg ml−1 for five (5) and small antibacterial activity with MIC50 = 191.85 μg ml−1 for | ||
| Antibacterial | Leaves | Water | Inhibition zone ranged from 16.4-17.3 mm with inhibitory effect against | ||
| Antibacterial | Flowers | Water | Antibacterial activity with inhibition zone ranged from 0 - 9.6 mm | ||
| Antibacterial | Aerial part rhizome | MeOH | Antibacterial activity with MIC = 15.63 and 62.5 mg of dry plant material ml−1 for | ||
| Antifungal | Leaf | EtOAc, MeOH, and water | Antifungal activity (MIC = 0.3–0.4 mg ml−1),compared to the positive control Bifonazole and Ketoconazole (MIC = 0.1–0.2 mg ml−1, MFC: 0.2–1.5 mg ml−1) | ||
| Yeast | Flowers and rachis | MeOH | Antimicrobial activity against | ||
| Antitubercular | Aerial parts | EtOAc n-hexane | The best activity was observed for p-coumaric acid ( | ||
| Anti-viral activity | Aerial parts | Hot water | CCFS-1/KMC (IC50 = 106.3 μg ml−1); RD cells (IC50 = 15.0 μg ml−1) inhibit EV71 infection by preventing viral replication and structural protein expression |
Notes.
TF-AgNPs, Tussilago farfara L. silver nanoparticles; MIC, the minimal inhibitory concentration; MBC, minimum bactericidal concentrations; IC50, the minimal concentration required to inhibit 50% cytopathic effect; G-: Gram negative bacteria; G+: Gram-positive bacteria; CCFS-1/KMC, human foreskin fibroblast; RD, human rhabdomyosarcoma.
Chemical antioxidant screening of coltsfoot.
| Assay-type | Solvent/extracts | Findings | Reference |
|---|---|---|---|
| FIA | Crude polysaccharides, polysaccharides | The IC50 value ascorbic acid < polysaccharides < crude polysaccharides | (Qin, K. et al., 2014) |
| Yeast | Water extracts | 20.9 inhibition of Yeast oxidation | |
| DPPH | MeOH extract | IC50 = 5 μg ml−1 while positive control BHT was 33 μg ml−1 | |
| DPPH | EtOAc MeOH Water | 28.79 mg TE/g extract DW | |
| 192.35 mg TE/g extract DW | |||
| 183.19 mg TE/g extract DW | |||
| DPPH | Water extracts | 198.9 μM Ascorbate equivalent/g | |
| Ethanol extracts | 113.5 μM Ascorbate equivalent/g | ||
| ABTS | EtOAc extracts | (41.08 mg TE/g extract DW | |
| MeOH extracts | (410.98 mg TE/g extract DW | ||
| Water extracts | (399.18 mg TE/g extract DW | ||
| ABTS | Phenolic content 30.03 mg GAE/g DW | 217.62 μM Trolox/g DW | |
| FRAP | Phenolic content 30.03 mg GAE/g DW | 455.64 μM Fe2+/g DW | |
| FRAP | EtOAc extracts | (49.98 mg TE/g extract DW | |
| MeOH extracts | (465.31 mg TE/g extract DW | ||
| Water extracts | (380.25 mg TE/g extract DW | ||
| CUPRAC | EtOAc extracts | (93.78 mg TE/g extract DW | |
| MeOH extracts | (677.09 mg TE/g extract DW | ||
| Water extracts | (453.38 mg TE/g extract DW | ||
| Phosphomolybdenm | EtOAc extracts | (1.54 mg TE/g extract DW | |
| MeOH extracts | (2.26 mg TE/g extract DW | ||
| Water extracts | (1.44 mg TE/g extract DW | ||
| Metal chelating | EtOAc extracts | (13.11 mg EDTAE/g DW | |
| MeOH extracts | (6.16 mg EDTAE/g DW | ||
| Water extracts | (4.98 mg EDTAE/g DW | ||
| NBT | EtOAc extract | IC50 = 1.8 μg ml−1 | |
| NBT | Quercetin-3-O-β-L-arabinopyranoside | IC50 = 12.9 μM | |
| IC50 = 35.6 μM | |||
| while quercetin IC50 = 63.9 μM |
Notes.
ABTS, 2:2′-azino-bis(3-ethylbenzothiazoline)-6-sulfonic acid.
BHT, a synthetic industrial antioxidant.
DPPH, 1:1-diphenyl-2-picrylhydrazyl.
DW, dry weight.
EDTAE, EDTA equivalents.
FIA, a flow injection analysis method.
FRAP, ferric reducing antioxidant power.
GAE, gallic acid equivalent; dry weight DW.
IC50, inhibitory concentration at 50% level.
TE, trolox equivalents.